

NAMS News



Don't Miss the NAMS Annual Meeting

Convening September 30–October 3 at the bayside Manchester Grand Hyatt in San Diego, CA, the NAMS 2009 Annual Meeting promises an exceptional scientific program and ample opportunities for networking with the world's experts. Review the Preliminary Program posted on the NAMS Web site (www.menopause.org/meetings/2009HCP.aspx) and register there, too.

Dr. Utian to be Honored at Special Events in San Diego

Here's another reason to attend the San Diego meeting. This is the last meeting for Dr. Wulf Utian, NAMS Founder and Executive Director, before he retires from NAMS and as Editor-in-Chief of *Menopause Management*. Join us on September 30 for the afternoon educational session—"20 Years of

Progress in Menopausal Medicine: The Utian Years"—and an evening reception with the theme of "Celebrating Wulf Utian." Whether or not you will be in San Diego, be sure to place a personal tribute message in the educational session's *Program*. Details can be found on the NAMS Web site (www.menopause.org/WUmessage.aspx).

Win Recognition and Cash Prizes for your Research

Researchers, this is your opportunity to present your work to menopause experts in a poster format (the deadline for submitting abstracts for consideration as oral presentations has passed). Up to four poster prizes will be awarded, with \$1,000 as the top prize. The online submission form is found at www.menopause.org/meetings/abstracts1call.aspx. Act quickly; the deadline for submitting late-breaking abstracts is July 31.

Have You Earned Your NCMP Credential?

Those of you who have successfully passed the NAMS competency examination may now use the credential "NCMP" (NAMS Certified Menopause Practitioner) every time you feature your name and other

Future NAMS Annual Meetings

20th NAMS Annual Meeting

September 30–October 3, 2009 • San Diego, CA

21st NAMS Annual Meeting

October 6–9, 2010 • Chicago, IL

22nd NAMS Annual Meeting

September 21–24, 2011 • Washington, DC

23rd NAMS Annual Meeting

October 3–6, 2012 • Orlando, FL

24th NAMS Annual Meeting

October 9–12, 2013 • Dallas, TX

NAMS Central Office

The North American Menopause Society
5900 Landerbrook Drive, Suite 390
Mayfield Heights, OH 44124

Mailing Address:

Post Office Box 94527 • Cleveland, OH 44101-4527

Phone: 440/442-7550 • Fax: 440/442-2660

E-mail Address: info@menopause.org

Web Site: <http://www.menopause.org>

credentials (eg, MD, NP, etc.). Interested in knowing what it takes to earn the credential? The next exam will take place on September 30, just before the NAMS Annual Meeting in San Diego. For more, go to the NAMS Web site (www.menopause.org/compexam.aspx).

NAMS Education on Medscape Popular

Currently, thousands are learning more about menopause from quality NAMS educational programs posted on Medscape. With one program about HT that was posted 8 months ago, a total of 5,882 have earned CME/CE and 28,953 have read the material, including 5,723 physicians. Join the crowd and learn! For more, go to the NAMS Web site (www.menopause.org/MS.aspx).

ADVERTISERS' INDEX

Bayer HealthCare Pharmaceuticals Inc.

Angeliq.....17-19

Eli Lilly & Co.

Evista6-10

North American Menopause Society, The.....4

Novo Nordisk Pharmaceuticals, Inc.

Vagifem.....IBC, OBC

Wyeth Pharmaceuticals Inc.

Premarin.....IFC, 1-2

Cardiovascular Corner

(continued from page 29)

6. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. *JAMA* 2002;288:321-33.
7. Centers for Disease Control and Prevention/National Center for Health Statistics. Data Brief. National Health and Nutrition Examination Survey. *Use of Hormone Replacement Therapy among Postmenopausal Women in the United States, 1988-94*. January 2003. (Available at: www.cdc.gov/nchs/data/nhanes/databriefs/hrtinwomen.pdf.) Accessed June 13, 2009.
8. Gambacciani M, Rosano GM, Monteleone P, et al. Clinical relevance of the HERS trial. *Lancet* 2002;360:641.
9. Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. *JAMA* 2007;297:1465-77.
10. Salpeter SR, Walsh JM, Greyber E, Salpeter EE. Brief report: coronary heart disease events associated with hormone therapy in younger and older women. A meta-analysis. *J Gen Intern Med* 2006;21:363-66.
11. Salpeter SR, Walsh JM, Greyber E, et al. Mortality associated with hormone replacement therapy in younger and older women: a meta-analysis. *J Gen Intern Med* 2004;19:791-804.
12. Taddei S, Virdis A, Ghiadoni L, et al. Menopause is associated with endothelial dysfunction in women. *Hypertension* 1996;28:576-82.
13. Virdis A, Ghiadoni L, Pinto S, et al. Mechanisms responsible for endothelial dysfunction associated with acute estrogen deprivation in normotensive women. *Circulation* 2000;101:2258-63.
14. Herrington DM, Braden GA, Williams JK, Morgan TM. Endothelial-dependent coronary vasomotor responsiveness in postmenopausal women with and without estrogen replacement therapy. *Am J Cardiol* 1994;73:951-52.
15. Kalantariou SN, Naka KK, Papanikolaou E, et al. Impaired endothelial function in young women with premature ovarian failure: normalization with hormone therapy. *J Clin Endocrinol Metab* 2004; 89:3907-13.
16. Volterrani M, Rosano G, Coats A, et al. Estrogen acutely increases peripheral blood flow in postmenopausal women. *Am J Med* 1995; 99:119-22.
17. Post WS, Goldschmidt-Clermont PJ, Wilhide CC, et al. Methylation of the estrogen receptor gene is associated with aging and atherosclerosis in the cardiovascular system. *Cardiovasc Res* 1999;43:985-91.
18. Clarkson TB, Appt SE. Controversies about HRT - lessons from monkey models. *Maturitas* 2005;51:64-74.
19. Hodis HN, Mack WJ, Lobo RA, et al. Estrogen in the prevention of atherosclerosis. A randomized, double-blind, placebo-controlled trial. *Ann Intern Med* 2001;135:939-53.
20. Karim R, Hodis HN, Stanczyk FZ, et al. Relationship between serum levels of sex hormones and progression of subclinical atherosclerosis in postmenopausal women. *J Clin Endocrinol Metab* 2008;93:131-138.
21. Karim R, Mack WJ, Lobo RA, et al. Determinants of the effect of estrogen on the progression of subclinical atherosclerosis: Estrogen in the Prevention of Atherosclerosis Trial. *Menopause*. 2005;12:366-73.
22. Hodis HN, Mack WJ, Lobo RA, et al. Hormone therapy and progression of coronary artery atherosclerosis in postmenopausal women. *N Engl J Med* 2003;349:535-45.
23. Herrington DM, Reboussin DM, Brosnihan KB, et al. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. *N Engl J Med* 2000;343:522-29.
24. Manson JE, Allison MA, Rossouw JE, et al. WHI and WHI-CACS Investigators. Estrogen therapy and coronary-artery calcification. *N Engl J Med* 2007;356:2591-2602.
25. Mendelsohn ME, Karas RH. Molecular and cellular basis of cardiovascular gender differences. *Science* 2005;308:1583-87.
26. Wynne FL, Payne JA, Cain AE, et al. Age-related reduction in estrogen receptor-mediated mechanisms of vascular relaxation in female spontaneously hypertensive rats. *Hypertension* 2004;43:405-12.
27. Vitale C, Mercurio G, Cerquetani E, et al. Time since menopause influences the acute and chronic effect of estrogens on endothelial function. *Arterioscler Thromb Vasc Biol* 2008;28:348-52.
28. Vitale C, Cornoldi A, Gebara O, et al. Interleukin-6 and flow-mediated dilatation as markers of increased vascular inflammation in women receiving hormone therapy. *Menopause* 2005;12:552-58.